MAPK1 and cancer: Intriguingly, MEK inhibitor selumetinib (Fig. S3C) suppressed the IFNγ‐induced development of low‐adherent cells (Fig. 3G) as well as the establishment of re‐adherence (see Fig. 3H, right), indicating crosstalk between IFNγ and MEK/Erk signalling pathways in the anoikis‐resistant cancer cell survival.